Ken Griffin Crinetics Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$43.83 - $54.98 $96,426 - $120,956	2,200 Added 43.14%	7,300 $372,000
Q2 2024 Aug 14, 2024	SELL	$42.12 - $51.91 $2.31 Million - $2.85 Million	-54,900 Reduced 91.5%	5,100 $228,000
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $1.2 Million - $1.61 Million	34,500 Added 135.29%	60,000 $2.81 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $215,208 - $311,388	-8,400 Reduced 24.78%	25,500 $907,000
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $523,816 - $1 Million	32,800 Added 2981.82%	33,900 $1.01 Million
Q2 2023 Aug 14, 2023	SELL	$15.73 - $23.6 $338,195 - $507,400	-21,500 Reduced 95.13%	1,100 $19,000
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $310,793 - $428,330	20,300 Added 882.61%	22,600 $362,000
Q4 2022 Feb 14, 2023	SELL	$15.49 - $19.05 $1.88 Million - $2.31 Million	-121,200 Reduced 98.14%	2,300 $42,000
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $182,911 - $225,937	-10,100 Reduced 7.56%	123,500 $2.43 Million

241

79.6M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $3.01B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.